NetworkNewsBreaks – InMed Pharmaceuticals Inc. (

NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Peer-Reviewed Study Results Published

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has announced that results of its study have been published in the “International Journal of Molecular Sciences.” The study was designed to evaluate the anti-inflammatory effects of rare cannabinoids and their potential application for the treatment of skin conditions, including atopic dermatitis, psoriasis, pruritus and acne. The study is titled “Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signalling Pathway.” According to the announcement, study results demonstrate the therapeutic potential of rare cannabinoids in the treatment of inflammatory skin conditions such as atopic dermatitis, psoriasis, pruritus and acne. The results also exhibited anti-inflammatory effects of CBC, THCV, CBG and CBGA and detail potential mechanisms of action on how rare cannabinoids can interact with specific skin-related endocannabinoid receptors. “This study provides further evidence of the ability of rare cannabinoids to exert anti-inflammatory effects in human keratinocytes through modifications of the endocannabinoid system and MAPK signalling,” said InMed Pharmaceutical scientific advisor Dr. Mauro Maccarrone in the press release. “Results from this study demonstrate important mechanisms of biological effects of rare cannabinoids and support the therapeutic potential of THCV and CBGA on inflammation-related skin conditions.”

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer